Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Lonhala Magnair Generic Name & Formulations
Legal Class
Rx
General Description
Glycopyrrolate 25mcg/mL; oral soln for inhalation.
Pharmacological Class
Long-acting anticholinergic.
How Supplied
Kit—60 vials (w. one Magnair device)
Manufacturer
Generic Availability
NO
Lonhala Magnair Indications
Indications
Long-term maintenance treatment of airflow obstruction in COPD, including chronic bronchitis and/or emphysema.
Lonhala Magnair Dosage and Administration
Adult
For oral inhalation use only with Magnair device. Administer at the same time of the day (AM + PM). Inhale contents of one vial (25mcg) twice daily.
Children
Not established.
Lonhala Magnair Contraindications
Not Applicable
Lonhala Magnair Boxed Warnings
Boxed Warning
Lonhala Magnair Warnings/Precautions
Warnings/Precautions
Do not initiate in patients during acutely deteriorating or potentially life-threatening COPD episodes. Not for treating acute symptoms. Do not exceed recommended dose. Discontinue immediately and treat if paradoxical bronchospasm or immediate hypersensitivity reactions occur; use alternative therapy. Narrow-angle glaucoma. Urinary retention. Prostatic hyperplasia. Bladder-neck obstruction. Labor & delivery. Pregnancy. Nursing mothers.
Lonhala Magnair Pharmacokinetics
See Literature
Lonhala Magnair Interactions
Interactions
Additive effects with concomitant other anticholinergic-containing drugs; avoid.
Lonhala Magnair Adverse Reactions
Adverse Reactions
Dyspnea, urinary tract infection, wheezing, upper respiratory tract infection, nasopharyngitis, peripheral edema, fatigue; paradoxical bronchospasm, hypersensitivity reactions.
Lonhala Magnair Clinical Trials
See Literature
Lonhala Magnair Note
Not Applicable
Lonhala Magnair Patient Counseling
See Literature
Images
